Ryan Chandanais, MS, CPhT

Ryan Chandanais, MS, CPhT
Ryan Chandanais is an Emerging Therapeutics Analyst at Diplomat Specialty Pharmacy in Flint, Michigan. His job is to gather, analyze, and present pipeline intelligence involving specialty drug products. He has additional drug development-related experience at a contract research organization for pre-clinical drug studies, where he served as a Research Associate and Report Coordinator. He holds a Master of Science in Integrative Pharmacology from Michigan State University and a Bachelor of Science in Education from Central Michigan University. He has acquired certifications as a Pharmacy Technician from the Pharmacy Technician Certification Board and a Laboratory Animal Technologist (LATG) from the American Association for Laboratory Animal Science.
The FDA issues a CRL when it decides that an application does not meet all the requirements for approval.
Dec 8, 2017 @08:09 AM
Speeding up the review of drugs to treat serious diseases makes sense. Here is a look at how it works.
Nov 16, 2017 @08:24 AM
It takes a great deal of time and resources for a manufacturer to complete all the necessary requirements to submit a successful NDA to the FDA for review.
Nov 1, 2017 @02:38 AM
The most impactful of the FDA designations, this status may be applied to drugs used to treat serious or life-threatening conditions.
Oct 18, 2017 @01:55 AM
Priority review voucher program is designed to focus attention on otherwise neglected diseases.
Dec 23, 2016 @03:09 AM
A number of manufacturers are developing drugs to treat NASH, and approximately 95 drugs are in the pipeline worldwide at various stages of development.
Sep 13, 2016 @06:53 AM
Chimeric antigen receptor (CAR) T-cell therapy has generated a lot of buzz in the drug development world.
May 26, 2016 @04:47 AM
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.